|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4600 AUD | -5.15% |
|
-9.80% | -29.23% |
| 06-24 | Recce Pharmaceuticals Requests Trading Halt Ahead of Equity Raise | MT |
| 06-22 | Recce Says HREC Approval Progresses Phase 3 Clinical Trial of Diabetic Foot Infections Treatment Candidate | MT |
| Market Cap | 133M 91.77M 80.79M 74.52M 69.7M 131M 8.65B 896M 347M 4.27B 345M 337M 14.85B | P/E 2026 * |
-6.48x | P/E 2027 * | -4.24x |
|---|---|---|---|---|---|
| Enterprise Value | 141M 97.39M 85.74M 79.09M 73.97M 139M 9.18B 950M 368M 4.53B 366M 358M 15.75B | EV / Sales 2026 * |
18.4x | EV / Sales 2027 * | 18.8x |
| Free-Float |
57.05% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -5.15% | ||
| 1 week | -9.80% | ||
| Current month | -16.36% | ||
| 1 month | -3.16% | ||
| 3 months | -2.13% | ||
| 6 months | -24.59% | ||
| Current year | -29.23% |
| 1 week | 0.46 |  | 0.5 |
| 1 month | 0.46 | | 0.59 |
| Current year | 0.42 | | 0.73 |
| 1 year | 0.28 | | 0.73 |
| 3 years | 0.28 | | 0.78 |
| 5 years | 0.28 | | 1.38 |
| 10 years | 0.13 | | 1.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 28/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 30/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 01/10/2012 |
James Graham
BRD | Director/Board Member | - | 01/05/2012 |
| Director/Board Member | - | 01/09/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 02-24 | Expiration | Chief Executive Officer | 2,250,000 | 0.7781% | ||
| 14/10/25 | Expiration | Chief Executive Officer | 745,962 | 0.3217% | ||
| 21/11/24 | Buy | Chairman | 2,650,000 | 1.1429% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.15% | -9.80% | +58.62% | -21.37% | 91.77M | |
| +0.92% | +0.47% | +43.59% | +143.50% | 996B | |
| +0.80% | +2.90% | +58.35% | +45.64% | 580B | |
| +0.06% | +6.17% | +26.59% | +72.81% | 415B | |
| +4.25% | -2.44% | +22.01% | +15.66% | 326B | |
| +0.31% | +5.51% | +31.09% | +40.06% | 280B | |
| +1.02% | +6.52% | +36.73% | +24.09% | 284B | |
| +1.32% | +12.60% | -27.54% | -41.32% | 210B | |
| +1.27% | +2.86% | +26.65% | +54.74% | 190B | |
| +0.09% | -0.23% | +16.75% | +61.56% | 155B | |
| Average | -0.17% | +1.70% | +29.29% | +39.54% | 343.68B | |
| Weighted average by Cap. | +0.30% | +2.17% | +33.91% | +68.12% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.68M 5.29M 4.66M 4.3M 4.02M 7.53M 499M 51.67M 20.01M 246M 19.88M 19.45M 857M | 8.86M 6.11M 5.38M 4.96M 4.64M 8.7M 576M 59.66M 23.11M 284M 22.95M 22.45M 989M |
| Net income | -20.45M -14.11M -12.42M -11.45M -10.71M -20.07M -1.33B -138M -53.32M -656M -52.96M -51.81M -2.28B | -30.9M -21.32M -18.77M -17.31M -16.19M -30.33M -2.01B -208M -80.58M -991M -80.03M -78.3M -3.45B |
| Net Debt | 8.15M 5.62M 4.95M 4.57M 4.27M 8M 530M 54.87M 21.25M 261M 21.11M 20.65M 910M | 33.53M 23.13M 20.36M 18.78M 17.57M 32.92M 2.18B 226M 87.43M 1.08B 86.84M 84.96M 3.74B |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/06/26 | A$0.4600 | -5.15% | 126,650 |
| 22/06/26 | A$0.4850 | +1.04% | 161,048 |
| 19/06/26 | A$0.4800 | 0.00% | 65,703 |
| 18/06/26 | A$0.4800 | -5.88% | 149,531 |
| 17/06/26 | A$0.5100 | +3.03% | 59,596 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
Select your edition
All financial news and data tailored to specific country editions
